NDAINJECTIONINJECTABLE
Approved
Dec 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CISPLATIN (cisplatin) by R-Pharm US is cross-links. First approved in 1978.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cisplatin is a platinum-based chemotherapy agent approved in 1978 that works by cross-linking DNA and interfering with transcription and replication, triggering cytotoxic cell death. It is administered via injection and has become a foundational agent across multiple solid tumor indications. The drug's broad activity and decades of clinical use establish it as a standard-of-care backbone in combination regimens.
LOE Approaching
As a mature, generic-exposed drug approaching LOE, cisplatin teams are typically small and focused on cost management and supply chain optimization rather than growth initiatives.
Mechanism of Action
cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Pharmacologic Class:
Platinum-based Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Started Sep 2026
33 enrolled
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Started Aug 2026
20 enrolled
Colon and Rectal Cancer
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Started May 2026
25 enrolled
Solid Tumor MalignanciesTesticular CancerHead and Neck Cancer+1 more
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
Started May 2026
192 enrolled
Upper Tract Urothelial Carcinoma
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Started May 2026
29 enrolled
Combined Hepatocellular and Cholangiocarcinoma
Worked on CISPLATIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.